Jim Cramer Sees Buying Opportunities in Praluent Patent Suit
After a court halts Regeneron's sales of Praluent, Jim Cramer sees opportunity in Amgen.
TheStreet's Jim Cramer sees Amgen (AMGN) - Get Report stock as being very cheap after a U.S. court blocked Regeneron (REGN) - Get Report and Sanofi (SNY) - Get Report from selling anti-cholesterol drug Praluent. Despite the court's decision, Cramer says Regeneron is also a buy.
